- Triglide 200 mg
- Triglide dosage
- Triglide drug
- Triglide triglide drug
- Triglide triglide dosage
- Triglide 120 mg
- Triglide dose range
- Triglide mg
- Triglide triglide 160 mg
- Triglide triglide 160 mg tablet
- Triglide oral dose
- Triglide tablet
- Triglide action
- Triglide effects of
- Triglide the effects of
- Triglide injection
Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect rates observed in clinical practice.
Adverse reactions reported by 2% or more of patients treated with fenofibrate (and greater than placebo) during double-blind, placebo-controlled trials are listed in Table 1. Adverse reactions led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo. Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.
Table 1: Adverse Reactions Reported by 2% or More of Patients Treated with Fenofibrate and Greater than Placebo During the Double-Blind, Placebo-Controlled Trials
|BODY SYSTEM |
|METABOLIC AND NUTRITIONAL DISORDERS|
|Abnormal Liver Tests||7.5%**||1.4%|
|Increased Creatine Phosphokinase||3.0%||1.4%|
|* Dosage equivalent to 200 mg fenofibrate capsules, micronized. Dosage comparable to 160 mg Triglide. |
** Significantly different from placebo.
The following adverse reactions have been identified during postapproval use of fenofibrate: myalgia, rhabdomyolysis, pancreatitis, muscle spasms, acute renal failure, hepatitis, cirrhosis, anemia, arthralgia, asthenia, and severely depressed HDL-cholesterol levels. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Included as part of the PRECAUTIONS section.
Triglide Drug Class
Triglide is part of the drug class:
Take fenofibrate exactly as prescribed by your doctor. Follow the directions on your prescription label carefully. Your doctor will determine the best dose for you. The dosage of fenofibrate must be individualized depending on other medicines you currently take, how you respond to fenofibrate therapy, and other medical conditions, such as renal function, you may have.
The recommended dose range of fenofibrate for the treatment of high cholesterol is 120 mg-160 mg.
The recommended dose range of fenofibrate for the treatment of high triglycerides is 35 mg- 150 mg.
The recommended dose range of fenofibrate for the treatment of hyperlipidemia is 105-135 mg.
If you take too much fenofibrate call your local Poison Control Center or seek emergency medical treatment right away.
Indications and Usage for Triglide
Primary Hypercholesterolemia or Mixed Dyslipidemia
Triglide is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides, and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
Triglide is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention.
Markedly elevated levels of serum triglycerides (e.g., >2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.
Important Limitations of Use
Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus [see Warnings and Precautions (5.1)].
Potentiation of coumarin-type anticoagulant effects has been observed with prolongation of the PT/INR.
Caution should be exercised when coumarin anticoagulants are given in conjunction with Triglide. The dosage of the anticoagulants should be reduced to maintain the PT/INR at the desired level to prevent bleeding complications. Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized [see Warnings and Precautions (5.6)].
Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including Triglide, there is a risk that an interaction will lead to deterioration of renal function. The benefits and risks of using Triglide with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed and renal function monitored.
Bile-Acid Binding Resins
Since bile-acid binding resins may bind other drugs given concurrently, patients should take Triglide at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption.
Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine.
Triglide - Clinical Pharmacology
Mechanism of Action
The active moiety of Triglide is fenofibric acid. The pharmacological effects of fenofibric acid in both animals and humans have been extensively studied through oral administration of fenofibrate.
The lipid-modifying effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferators activated receptor α (PPARα). Through this mechanism, fenofibrate increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity).
The resulting decrease in TG produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be artherogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. Activation of PPARα also induces an increase in the synthesis of apoproteins A-I, A-II and HDL-cholesterol.
Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid.
A variety of clinical studies have demonstrated that elevated levels of TC, LDL-C, and apo B, an LDL membrane complex, are associated with human atherosclerosis. Similarly, decreased levels of HDL-C and its transport complex, apolipoprotein A (apo AI and apo AII) are associated with the development of atherosclerosis. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of TC, LDL-C, and triglycerides (TG), and inversely with the level of HDL-C. The independent effect of raising HDL-C or lowering TG on the risk of cardiovascular morbidity and mortality has not been determined.
Fenofibric acid, the active metabolite of fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apo AI and apo AII.
Triglide 160 mg tablet was shown to have comparable bioavailability to a single dose of 200 mg fenofibrate capsule, micronized. Fenofibrate is a pro-drug of the active chemical moiety fenofibric acid. Fenofibrate is converted by ester hydrolysis in the body to fenofibric acid which is the active constituent measurable in the circulation.
Absorption: The absolute bioavailability of fenofibrate cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection. Fenofibrate is insoluble in water and its bioavailability is optimized when taken with meals. However, after fenofibrate is dissolved, fenofibrate is well absorbed from the gastrointestinal tract. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate, and 25% was excreted in the feces. Peak plasma levels of fenofibric acid occur an average of 3 hours after administration. The extent of absorption of Triglide (AUC) is comparable between fed and fasted conditions. Food increases the rate of absorption of Triglide approximately 55%.
Distribution: In healthy volunteers, steady-state plasma levels of fenofibric acid were shown to be achieved within a week of dosing and did not demonstrate accumulation across time following multiple dose administration. Serum protein binding was approximately 99% in normal and hyperlipidemic subjects.
Metabolism: Following oral administration, fenofibrate is rapidly hydrolyzed by esterases to the active metabolite, fenofibric acid; no unchanged fenofibrate is detected in plasma. Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. A small amount of fenofibric acid is reduced at the carbonyl moiety to a benzhydrol metabolite which is, in turn, conjugated with glucuronic acid and excreted in urine. In vivo metabolism data indicate that neither fenofibrate nor fenofibric acid undergo oxidative metabolism (e.g., cytochrome P450) to a significant extent.
Elimination: After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide. After administration of radiolabelled fenofibrate, approximately 60% of the dose appeared in the urine and 25% was excreted in the feces. Fenofibric acid is eliminated with a half-life of approximately 16 hours, allowing once daily dosing.
Geriatrics: In elderly volunteers 77 to 87 years of age, the oral clearance of fenofibric acid following a single oral dose of fenofibrate was 1.2 L/h, which compares to 1.1 L/h in young adults. This indicates that a similar dosage regimen can be used in the elderly, without increasing accumulation of the drug or metabolites.
Pediatrics: Pharmacokinetics of Triglide has not been studied in pediatric patients.
Gender: No pharmacokinetic difference between males and females has been observed for fenofibrate.
Race: The influence of race on the pharmacokinetics of fenofibrate has not been studied; however, fenofibrate is not metabolized by enzymes known for exhibiting inter-ethnic variability.
Renal Impairment: The pharmacokinetics of fenofibric acid was examined in patients with mild, moderate, and severe renal impairment. Patients with severe renal impairment (creatinine clearance [CrCl ≤ 30 mL/min] < 30 mL/min or estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2) showed 2.7-fold increase in exposure for fenofibric acid and increased accumulation of fenofibric acid during chronic dosing compared to that of healthy subjects. Patients with mild to moderate renal impairment (CrCl 30-80 mL/min or eGFR 30-59 mL/min/1.73 m2) had similar exposure but an increase in the half-life for fenofibric acid compared to that of healthy subjects. Based on these findings, avoid use of Triglide in patients with mild or moderate renal impairment. Triglide is contraindicated for patients with severe renal impairment, including end-stage renal disease (ESRD) or those receiving dialysis [see Contraindications (4) and Use in Special Populations (8.6)].
Hepatic Impairment: No pharmacokinetic studies have been conducted in patients having hepatic impairment.
Drug-Drug Interactions:In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C8, CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.
Table 2 describes the effects of co-administered drugs on fenofibric acid systemic exposure.
Table 3 describes the effects of fenofibrate on co-administered drugs.
Table 2. Effects of Co-Administered Drugs on Fenofibric Acid Systemic Exposure from Fenofibrate Administration
|Co-Administered Drug ||Dosage Regimen of Co-Administered Drug ||Dosage Regimen of Fenofibrate ||Changes in Fenofibric Acid Exposure |
| || || ||AUC ||Cmax |
|Lipid-lowering agents |
|Atorvastatin ||20 mg once daily for 10 days ||Fenofibrate 160 mg1 once daily for 10 days ||↓2% ||↓4% |
|Pravastatin ||40 mg as a single dose ||Fenofibrate 3 × 67 mg2 as a single dose ||↓1% ||↓2% |
|Fluvastatin ||40 mg as a single dose ||Fenofibrate 160 mg1 as a single dose ||↓2% ||↓10% |
|Anti-diabetic agents |
|Glimepiride ||1 mg as a single dose ||Fenofibrate 145 mg1 once daily for 10 days ||↑1% ||↓1% |
|Metformin ||850 mg three times daily for 10 days ||Fenofibrate 54 mg1 three times daily for 10 days ||↓9% ||↓6% |
|Rosiglitazone ||8 mg once daily for 5 days ||Fenofibrate 145 mg1 once daily for 14 days ||↑10% ||↑3% |
1TriCor (fenofibrate) oral tablet
2TriCor (fenofibrate) oral micronized capsule
Table 3. Effects of Fenofibrate on Systemic Exposure of Co-Administered Drugs
Dosage Regimen of Fenofibrate
Dosage Regimen of
Change in Co-Administered Drug Exposure
Fenofibrate 160 mg1 once daily for 10 days
Atorvastatin, 20 mg once daily for 10 days
Fenofibrate 3 × 67 mg2 as a single dose
Pravastatin, 40 mg as a single dose
Fenofibrate 160 mg1 as a single dose
Fluvastatin, 40 mg as a single dose
Fenofibrate 145 mg1 once daily for 10 days
Glimepiride, 1 mg as a single dose
Fenofibrate 54 mg1 three times daily for 10 days
Metformin, 850 mg three times daily for 10 days
Fenofibrate 145 mg1once daily for 14 days
Rosiglitazone, 8 mg once daily for 5 days
1TriCor (fenofibrate) oral tablet
2TriCor (fenofibrate) oral micronized capsule
Patient Counseling Information
Instruct patients to take Triglide once daily at the prescribed dose, swallowing each tablet whole. Additionally, instruct patients not to take chipped or broken tablets.
Instruct patients to keep Triglide in the original bottle to protect from moisture. The bottle contains a desiccant in the cap to protect tablets from moisture. Tablets should not be stored or placed in any other container, such as pill boxes or pill organizers.
Instruct patients to continue following an appropriate lipid-modifying diet while taking Triglide.
Advise patients not to use Triglide if they have a known hypersensitivity to fenofibrate or fenofibric acid.
Advise patients to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever; onset of abdominal pain or other symptoms consistent with gallstones or pancreatitis; or any other new symptoms.
Inform patients that if they are taking coumarin anticoagulants, Triglide may increase their anti-coagulant effect and that increased monitoring may be necessary.
Advise patients regarding medications that should not be taken in combination with Triglide or that may necessitate increased monitoring. Instruct patients to inform their health care providers regarding all medications, supplements, and herbal preparations that they are taking.
Casper Pharma LLC
East Brunswick, NJ 08816
Aenova France SAS, (SkyePharma Production SAS)
38291 Saint-Quentin-Fallavier, France
Made in France
© Casper Pharma LLC. All rights reserved.
What other drugs will affect Triglide (fenofibrate)?
Tell your doctor about all medicines you use, and those you start or stop using during your treatment with fenofibrate, especially:
other cholesterol lowering medicines;
a blood thinner (warfarin, Coumadin, Jantoven); or
drugs that weaken immune system such as cancer medicine, steroids, and medicines to prevent organ transplant rejection.
This list is not complete. Other drugs may interact with fenofibrate, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.